AVEN has been identified as an inhibitor of apoptosis, which binds to the adaptor protein, APAF-1, and thereby prevents apoptosome formation and mitochondrial apoptosis. Recent data have demonstrated high expression levels of AVEN messenger RNA in acute leukemias as well as a positive correlation between AVEN mRNA overexpression and poor prognosis in childhood acute lymphoblastic leukemia. On the basis of these data, we investigated the potential involvement of AVEN in tumorigenesis. First, we confirmed the overexpression of AVEN in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patient samples. We then established a transgenic mouse model with T-cell-specific overexpression of AVEN, with which we demonstrated the oncogenic cooperation of AVEN with heterozygous loss of p53. Finally, we used a subcutaneous xenograft mouse model to show that AVEN knockdown in the T-ALL cell lines, MOLT-4 and CCRF-CEM, and in the acute myeloblastic leukemia cell line, Kasumi-1, leads to a halt in tumor growth owing to the increased apoptosis and decreased proliferation of tumor cells. Collectively, our data demonstrate that the anti-apoptotic molecule, AVEN, functions as an oncoprotein in hematopoietic neoplasms.
INTRODUCTION
The acquired capability of tumor cells to withstand diverse apoptotic stimuli represents a well-recognized characteristic of cancer, 1,2 and in recent years, additional forms of cell death have been identified that have a role in the tumor suppressor function of 'programmed cell death'. Two main apoptotic signaling pathways have been wellcharacterized: the death receptor (extrinsic) and the mitochondrial (intrinsic) pathways. 3 Mutational interference in both pathways has been identified in many tumors. 4, 5 Abrogation of the mitochondrial pathway is a particularly important step in the development of tumor cell resistance to classical chemotherapy and radiation treatment. [6] [7] [8] Both the inactivation of pro-apoptotic tumor suppressor molecules and the overexpression of anti-apoptotic oncoproteins, such as BCL-2, have been frequently reported to contribute to the loss of mitochondrial apoptosis sensitivity as well as tumor initiation and development.
The formation of the so-called apoptosome complex is central to the intrinsic apoptotic signal transduction pathway. The apoptotic stimulus promotes the BCL-2 family-regulated release of Cytochrome c (Cytc) from the mitochondria into the cytosol, where it binds to the adaptor protein APAF-1 and subsequently induces APAF-1 oligomerization and Caspase-9 recruitment. 6 The resulting apoptosome complex serves as both the platform for Caspase-9 activation and the molecular trigger for the deathexecuting caspase cascade. 9 Several regulators of apoptosome activity have been described, including the anti-apoptotic protein, AVEN. 10 Originally identified in a yeast-two-hybrid screen as a binding partner of BCL-x L , AVEN has also been shown to interact with APAF-1 and inhibit apoptosome formation. 11 In addition to its inhibitory function in mitochondrial apoptosis, AVEN has also recently been shown to function as an activator of the cell cycle-regulating ATM kinase in the DNA damage response pathway. 12, 13 Evidence supporting the oncogenic involvement of AVEN in the inhibition of apoptosis is based on studies describing the high mRNA expression levels observed in acute leukemias. In the first manuscript by Paydas et al., the authors investigated a study group consisting of 37 acute myeloblastic leukemia (AML) and 28 acute lymphoblastic leukemia (ALL) patients. 14 The details regarding the number of ALL patients who were either of the frequent B cell type or had developed T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) were not given. The authors of this study noticed elevated AVEN mRNA expression levels of acute leukemias and suggested that AVEN might represent a novel prognostic indicator for acute leukemia. A second paper by Choi et al. describes a positive correlation between AVEN mRNA overexpression and poor prognosis in childhood ALL. 15 Again, no data were presented regarding whether T-ALL samples were included in the study.
The overexpression of AVEN in tumors would not come as a surprise, as it is a cell death-repressing protein; however, no direct experimental proof has been published on the oncogenic potential of AVEN until now. Here, we demonstrate strong overexpression of AVEN in acute leukemia/lymphoma, particularly in T-ALLs, thereby confirming the correlation between AVEN expression and the development of acute leukemias. We analyzed a transgenic mouse model with T-cell-specific AVEN overexpression on a heterozygous p53 þ / À knockout background and found a significant increase in the development of T-cell lymphoma compared with p53 þ / À heterozygous knockout animals with normal Aven expression levels in thymocytes and T cells. In addition, the results obtained using human leukemic AVEN knockdown cell lines in a xenograft mouse model imply that AVEN expression is required for robust tumor formation and progression. Collectively, we obtained significant experimental evidence that the apoptosis inhibitor, AVEN, exhibits oncogenic potential during development of hematopoietic neoplasms.
RESULTS AND DISCUSSION
The overexpression of AVEN in both AML and ALL has been reported, 14, 15 although the ALL results were not further distinguished between the common B-ALL and rare T-ALL cases. The latter subtypes seem to be quite heterogeneous with regard to their molecular pathogenesis. [16] [17] [18] [19] [20] We analyzed tumor material derived from eight patients with T-ALL/T-lymphoblastic lymphoma (WHO classification, 21 In total, 7 of the 8 T-ALL/T-lymphoblastic lymphoma samples examined by IHC displayed AVEN (over-) expression, whereas 6 of the 13 B-ALL samples expressed AVEN. To verify that the high AVEN expression levels are not merely associated with the immature state of the T-ALL cells, we quantified the AVEN expression levels in human thymocytes by IHC analysis and did not detect a significant staining for AVEN. We also performed FACS sorting of various mouse thymocyte subpopulations followed by western blot analysis of lysates prepared from double-negative CD4 À CD8 À , double-positive CD4 þ CD8 þ , and single-positive CD4 þ and CD8 þ cells and did not find significant differences in the AVEN expression levels (data not shown). These results confirm a positive correlation between AVEN (over-) expression and ALL leukemogenesis and suggest that AVEN fulfills a possible oncogenic function in T-ALLs.
To obtain direct experimental evidence that AVEN has an oncogenic role in T-cell leukemia, we established a transgenic mouse model with T-cell-specific expression of the human AVEN protein. For this purpose, AVEN cDNA was cloned under the control of the proximal lck promoter, 22 which is active in thymocytes and mature T cells (Figure 2a ). One founder mouse was identified by Southern blot, and offspring of the transgenic mouse line were assessed by PCR ( Figure 2b ) and Southern blot ( Figure 2c ) to genotype wild-type, heterozygous and homozygous lck AVEN transgenic animals. Figure 2d demonstrates the strong overexpression of AVEN protein in T cells of the spleen and lymph nodes as well as in thymocytes. AVEN expression levels were greater in homozygous transgenic mice compared with heterozygous animals. As we obtained only one founder mouse line, we determined and analyzed the integration site of the lck AVEN transgene to exclude possible insertional mutagenesis of tumor suppressor genes or neighboring oncogenes. mFISH and LAM-PCR analysis revealed the integration of the transgenic DNA in mouse chromosome 6 B85 kb upstream of the cellular gene Reg3g (see Supplementary Figure 1 ). The integration of the transgene at this locus, a great distance from any cellular gene, is highly unlikely to result in tumor-promoting insertional mutagenesis. Three different cases of T-lymphoblastic lymphoma. IHC analysis was performed according to standard protocols using the polyclonal rabbit antibody against human AVEN (NT, Pro Sci 2417) at a 1:1000 dilution. Antibody specificity was validated using MCF-7 cells with and without AVEN knockdown. Although cells of the infiltratefree bone marrow do not show significant AVEN expression (a) and only single blasts within a normal germinal center express AVEN (whereas many others do not; e), all human T-lymphoblastic leukemia/lymphoma cells display high amounts of AVEN protein
AVEN has been identified as an inhibitor of apoptosis. 11 Therefore, we aimed to investigate whether transgenic overexpression of AVEN influences apoptosis in T cells. We isolated thymocytes from homozygous lck AVEN transgenic and wild-type mice, which were then incubated for 24 h with the mitochondrial apoptosis inducer, etoposide (Figure 2e ). The AVEN-overexpressing thymocytes were less sensitive towards etoposide treatment, thereby confirming the anti-apoptotic properties of AVEN.
We examined the lck AVEN transgenic mice for T-cell lymphomagenesis and observed no tumor development in these animals on a wild-type C57Bl/6 genetic background (data not shown). Next, we investigated whether AVEN overexpression would cooperate as an oncoprotein with loss of the tumor suppressor p53 in T-cell lymphoma. 23, 24 For this purpose, we bred the lck AVEN mouse line with p53 knockout animals. We did not observe any further acceleration of lymphoma development in homozygous p53
À / À knockout mice, following homozygous transgenic AVEN overexpression in thymocytes (data not shown). However, any subtle influence of a weak oncogene on tumor development would probably not be detected in the context of the fast T-cell lymphoma occurrence seen in homozygous p53 þ / À background became terminally ill with lymphomas in the same time frame (Figure 3a) . None of the 20 wild-type control mice developed tumors. Our findings provide strong evidence that AVEN displays oncogenic potential in a transgenic mouse model. However, as our data were obtained using a single lck AVEN transgenic mouse line, we cannot completely rule out the possibility of a distant effect associated with the integration site on the oncogenic phenotype. However, the likelihood of such an influence is rather small, as the integration site is localized a large distance from the neighboring genes. Figure 3b demonstrates that transgenic overexpression of AVEN does not influence the type of thymic lymphoma developing in a p53-deficient background. As in p53 À / À -deficient mice with wild-type Aven expression levels, [23] [24] [25] additional homozygous overexpression of AVEN leads to the manifestation of thymic lymphomas with CD4 þ CD8 þ double-positive tumor cells resembling an immature thymocyte phenotype.
We were also interested in investigating whether transgenic AVEN overexpression would cooperate with the oncoprotein, LMO2, in lymphomagenesis. LMO2 is a nuclear protein that, together with many other proteins (for example, TAL1, E47, GATA-1 and LDB1), forms a functional multi-protein transcriptional complex binding to DNA, which regulates the expression of genes important for differentiation. LMO2 activation has been implicated in the development of human and mouse T-ALL. To investigate the potential oncogene cooperation between AVEN and LMO2, we performed transplantation experiments. Lineage negative (Lin À ) bone marrow cells isolated from homozygous lck AVEN and wild-type donor mice were transduced with either a retroviral LMO2 expression vector or an empty control vector, and then injected intravenously into lethally irradiated recipient SJL mice. As expected, LMO2 overexpression in transplanted hematopoietic stem and progenitor cells led to the development of lymphomas in all injected mice. However, additional overexpression of AVEN did not accelerate the development of LMO2-driven hematopoietic malignancies, suggesting that Aven does not cooperate with LMO2 in lymphoma development (Supplementary Figure 2) . In contrast, we observed a slight delay in the onset of lymphomagenesis in animals transplanted with LMO2-transduced lck AVEN cells compared with mice transplanted Figure 2 . Tissue-specific overexpression of AVEN inhibits etoposideinduced apoptosis in transgenic mouse T cells. (a) A schematic presentation of the transgenic construct. Human AVEN cDNA is specifically expressed in mouse T cells under the control of the distal lck promoter. 22 Genomic hGH sequences at the 3 0 -end enhance transgene expression. The 6.6 kb SpeI/SpeI fragment consisting of the lck promoter, AVEN cDNA and hGH sequences was excised and injected into the pronuclei of FVB/N-derived zygotes, which were then transplanted into CD1 foster female mice. (b, c) A PCR reaction with AVEN and hGH-specific primers was performed to identify positive founder animals by amplifying a 400 bp DNA fragment (b; ' þ ': positive transgenic mice, ' À ': wild-type mice), which was confirmed by Southern blot analysis using EcoRIdigested genomic tail DNA and a hGH-specific 32 [P]-labeled probe (c; 'þ / þ ': homozygous transgenic mice, ' þ / À ': heterozygous transgenic mice, 'wt': wild-type mice). The heterozygous mice were distinguished from the homozygous animals based on the strength of the Southern blot signal, and the genotypes were confirmed by analyzing the offspring derived after mating transgenic mice with wild-type animals (homozygous lck AVEN þ / þ mice yielded 100% heterozygous lck AVEN þ / À offspring upon mating with wild-type animals). (d) Western blot analysis of transgenic AVEN expression in spleen, lymph nodes and thymus. Protein lysates (25 mg) derived from various hematopoietic organs of wild-type, heterozygous and homozygous lck AVEN transgenic mice were loaded onto an SDS-PAGE gel. Following electrophoresis and semi-dry transfer, the membrane was incubated with self-raised anti-AVEN antiserum derived against a carboxy-terminal peptide (amino-acid sequence identical for human and mouse AVEN: KNVTEEELEDWLDSMIS). Ponceau S staining of the membrane served as loading control.
(e) Apoptosis analysis with lck AVEN transgenic and wild-type thymocytes. Cell death was measured using the Nicoletti assay 28 
h after incubation with or without etoposide (5 mM).
Four experiments were performed, and error bars represent s.e. ** indicates 0.01XpX0.001 (P ¼ 0.005; paired t-test).
with LMO2-transduced wild-type cells. However, the slope of both Kaplan-Meier curves was identical, and we do not believe that AVEN interferes with LMO2-induced lymphoma development.
We proposed to complement our oncogenic AVEN overexpression studies with AVEN knockdown experiments using human leukemia cell lines. We stably transduced the human T-ALL cell line, MOLT-4 (ATCC no. CRL-1582), with either AVEN short hairpin RNA (shRNA) in the lentiviral vector pLKO.1-tdTomato nucmem or non-targeting control shRNA in the same vector. In addition, the human T-ALL cell line, CCRF-CEM (ATCC no CCL-119), was transduced with the same shRNA sequences in the pLKO.1 puro vector. Efficient AVEN knockdown was confirmed via Western blot analysis (Figures 4A and B) . Our in vitro expansion assays revealed that the number of AVEN knockdown MOLT-4 and CCRF-CEM cells increased at a significantly slower rate than the corresponding cells transduced with control shRNA (see Supplementary Figure 3) . We then injected either AVEN knockdown or control shRNA-transduced MOLT-4 or CCRF-CEM cells into the right flanks of immunocompromised NOD/SCID mice 26 and monitored tumor growth. As shown in Figure 4A , only MOLT-4 cells transduced with control shRNA, which retain normal AVEN protein levels, formed exponentially growing subcutaneous tumors. In contrast, the downregulation of AVEN mediated by lentiviral shRNA strongly diminished the tumorigenicity of MOLT-4 cells in immunodeficient mice. A similar effect of diminished tumor growth in the absence of AVEN was observed in the xenograft tumors established with CCRF-CEM cells ( Figure 4B ).
After the mice were sacrificed, tumors were explanted and weighed. In both xenograft models, MOLT-4 and CCRF-CEM, tumors established with AVEN shRNA-transduced cells weighed significantly less than tumors derived from the control shRNAtransduced cells (Supplementary Figures 4A and B) .
An additional xenograft transplantation assay was performed using the human AML cell line, Kasumi-1 (ATCC no. CRL-2724 27 ), which was transduced with the pLKO.1tdTomato nucmem lentiviral AVEN knockdown construct to obtain a significant reduction in the endogenous AVEN protein levels (Supplementary Figure 4C ). Again, we injected either AVEN knockdown or control shRNA-transduced Kasumi-1 cells into the flanks of NOD/SCID mice and assessed tumor growth. The result of this in vivo xenograft transplantation experiment is shown in Supplementary Figure 4C . Whereas the tumors established with AVEN-expressing Kasumi-1 cells grew exponentially, tumor growth was severely diminished in AVEN knockdown cells. This result, obtained in a third leukemic AML cell line, substantiates the evidence that the apoptosis inhibitor, AVEN, has an important role in leukemia development and progression.
We performed additional IHC analyses with the xenografted MOLT-4-derived tumors to gain further insight into the consequences of AVEN knockdown in tumor cells. As confirmed by positive anti-hCD3 and anti-hCD4 staining of tumor-derived slides, the tumor mass was built up by MOLT-4 cells ( Figure 4C: a,b,f,g ). Using anti-Ki67 (MIB-1) and anti-phospho-HISTONE H3 (pHH3) antibodies, decreased numbers of proliferating cells were detected in AVEN-deficient MOLT-4-derived tumors compared with MOLT-4 tumors with normal AVEN expression ( Figure 4C : c,d,h,i). Of note, HISTONE H3 is not phosphorylated during apoptosis, and therefore, the anti-pHH3 staining allows for the distinction between genuine mitoses and apoptotic nuclei. In addition, we noticed a profound increase in the apoptosis of MOLT-4 tumor cells upon knockdown of AVEN when compared with tumors induced by MOLT-4 cells with normal AVEN levels, as revealed by anti-cleaved hCaspase-3 staining ( Figure 4C : e,j). Collectively, these IHC results demonstrate that AVEN expression in the T-ALL cell line, MOLT-4, and possibly, in other leukemia cell lines and primary tumor cells, is required for both the proliferation and suppression of apoptosis, two properties that would sufficiently explain the oncogenic potential of AVEN.
In 2008, Guo et al. have reported that AVEN inhibits the entry into mitosis in Xenopus egg extracts and that it is able to function as an ATM activator to inhibit G2/M progression. 13 Immunodepletion of AVEN allowed for mitotic entry even in the presence of damaged DNA, and collectively, the results implicate AVEN in the ATM-dependent DNA damage response pathway. On the basis of these findings, one would expect that, in addition to its oncogenic function as a cell death inhibitor, AVEN can also exert a tumor suppressor function by inhibiting mitotic entry, specifically upon DNA damage. However, the findings presented here (that is, AVEN overexpression in human T-ALL samples, oncogenic AVEN cooperation in heterozygous p53 þ / À mice, and reduced tumorigenicity in AVEN knockdown T-ALL cell lines measured in a xenograft mouse tumor model) suggest that AVEN functions as an oncoprotein rather than a tumor suppressor, at least in acute lymphomas. þ / À mice (25%) died of T-cell leukemia. This represents a significant increase in leukemogenesis (log-rank test, Po0.014). In each group, one animal developed a sarcoma; these animals were excluded from the statistical calculations. (b) After crossing with lck AVEN transgenic animals, heterozygous and homozygous p53 knockout mice predominantly develop the same immature CD4 þ CD8 þ double-positive thymic lymphomas as observed in non-AVEN transgenic p53-deficient mice. 23 FACS analysis was performed with normal thymocytes isolated from a wild-type C57Bl/6 mouse and T-cell leukemia cells isolated from an 
